APAF1
Basic information
Region (hg38): 12:98645149-98735433
Links
Phenotypes
GenCC
Source:
- depressive disorder (Limited), mode of inheritance: AD
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the APAF1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 10 | |||||
missense | 44 | 55 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 1 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 2 | 2 | 4 | |||
non coding | 2 | |||||
Total | 0 | 0 | 45 | 16 | 7 |
Variants in APAF1
This is a list of pathogenic ClinVar variants found in the APAF1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
12-98648396-A-G | not specified | Uncertain significance (Aug 16, 2021) | ||
12-98648451-G-C | not specified | Uncertain significance (Apr 22, 2024) | ||
12-98648458-A-AT | Neural tube defect | Uncertain significance (Jan 01, 2013) | ||
12-98648666-T-C | not specified | Uncertain significance (Mar 25, 2024) | ||
12-98648692-G-A | not specified • EBV-positive nodal T- and NK-cell lymphoma | Likely benign (Jan 04, 2022) | ||
12-98648758-A-C | not specified | Uncertain significance (Jun 22, 2021) | ||
12-98648761-C-T | not specified | Uncertain significance (Nov 14, 2023) | ||
12-98648774-C-T | not specified | Uncertain significance (Feb 14, 2023) | ||
12-98648780-G-A | not specified | Likely benign (Sep 06, 2022) | ||
12-98649592-G-T | not specified | Uncertain significance (Nov 03, 2023) | ||
12-98649597-C-A | not specified | Uncertain significance (May 23, 2024) | ||
12-98659150-C-T | APAF1-related disorder | Likely benign (May 08, 2019) | ||
12-98659309-C-T | not specified | Uncertain significance (Jan 24, 2024) | ||
12-98662491-G-C | not specified | Uncertain significance (Sep 29, 2023) | ||
12-98662511-A-G | not specified | Uncertain significance (Jun 07, 2023) | ||
12-98662517-T-A | not specified | Uncertain significance (May 26, 2024) | ||
12-98662753-T-A | not specified | Uncertain significance (Sep 06, 2022) | ||
12-98662763-A-G | APAF1-related disorder | Likely benign (Feb 26, 2020) | ||
12-98665549-A-T | APAF1-related disorder | Likely benign (Feb 21, 2019) | ||
12-98665576-A-G | not specified | Uncertain significance (Sep 20, 2023) | ||
12-98665606-C-T | not specified | Uncertain significance (Dec 16, 2023) | ||
12-98665674-T-C | APAF1-related disorder | Benign (Dec 31, 2019) | ||
12-98665705-A-G | not specified | Uncertain significance (Jul 14, 2023) | ||
12-98665717-A-G | not specified | Uncertain significance (Mar 16, 2022) | ||
12-98665722-C-T | Likely benign (Jul 31, 2018) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
APAF1 | protein_coding | protein_coding | ENST00000551964 | 26 | 90286 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00000962 | 1.00 | 125620 | 0 | 128 | 125748 | 0.000509 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.43 | 544 | 646 | 0.841 | 0.0000323 | 8276 |
Missense in Polyphen | 107 | 184.08 | 0.58127 | 2366 | ||
Synonymous | -0.402 | 234 | 226 | 1.03 | 0.0000117 | 2277 |
Loss of Function | 5.14 | 22 | 67.7 | 0.325 | 0.00000322 | 844 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00234 | 0.00235 |
Ashkenazi Jewish | 0.0000992 | 0.0000992 |
East Asian | 0.0000544 | 0.0000544 |
Finnish | 0.000231 | 0.000231 |
European (Non-Finnish) | 0.000440 | 0.000440 |
Middle Eastern | 0.0000544 | 0.0000544 |
South Asian | 0.000786 | 0.000784 |
Other | 0.000326 | 0.000326 |
dbNSFP
Source:
- Function
- FUNCTION: Oligomeric Apaf-1 mediates the cytochrome c-dependent autocatalytic activation of pro-caspase-9 (Apaf-3), leading to the activation of caspase-3 and apoptosis. This activation requires ATP. Isoform 6 is less effective in inducing apoptosis. {ECO:0000269|PubMed:10393175, ECO:0000269|PubMed:12804598}.;
- Pathway
- Legionellosis - Homo sapiens (human);p53 signaling pathway - Homo sapiens (human);Small cell lung cancer - Homo sapiens (human);Apoptosis - multiple species - Homo sapiens (human);Alzheimer,s disease - Homo sapiens (human);Amyotrophic lateral sclerosis (ALS) - Homo sapiens (human);Huntington,s disease - Homo sapiens (human);Tuberculosis - Homo sapiens (human);Pathways in cancer - Homo sapiens (human);Hepatitis B - Homo sapiens (human);Parkinson,s disease - Homo sapiens (human);Apoptosis - Homo sapiens (human);miRNA Regulation of DNA Damage Response;Apoptosis Modulation and Signaling;Alzheimers Disease;TNF alpha Signaling Pathway;Parkinsons Disease Pathway;Amyotrophic lateral sclerosis (ALS);Nanomaterial induced apoptosis;Integrated Lung Cancer Pathway;Apoptosis;Fas Ligand (FasL) pathway and Stress induction of Heat Shock Proteins (HSP) regulation;Apoptotic Signaling Pathway;TP53 Regulates Transcription of Cell Death Genes;Apoptosis Modulation by HSP70;Oxidative Damage;Protein alkylation leading to liver fibrosis;miRNA regulation of p53 pathway in prostate cancer;apoptotic signaling in response to dna damage;DNA Damage Response;Neutrophil degranulation;Gene expression (Transcription);trefoil factors initiate mucosal healing;caspase cascade in apoptosis;role of mitochondria in apoptotic signaling;hiv-1 nef: negative effector of fas and tnf;west nile virus;stress induction of hsp regulation;regulation of cell cycle progression by plk3;Transcriptional Regulation by E2F6;Generic Transcription Pathway;Fas;TP53 Regulates Transcription of Cell Death Genes;RNA Polymerase II Transcription;Formation of apoptosome;Apoptotic factor-mediated response;Intrinsic Pathway for Apoptosis;Innate Immune System;Immune System;Apoptosis;Programmed Cell Death;Activation of caspases through apoptosome-mediated cleavage;TP53 Regulates Transcription of Caspase Activators and Caspases;Transcriptional Regulation by TP53;Direct p53 effectors;TNF;Cytochrome c-mediated apoptotic response;Caspase Cascade in Apoptosis;HIV-1 Nef: Negative effector of Fas and TNF-alpha;p75(NTR)-mediated signaling;E2F transcription factor network
(Consensus)
Recessive Scores
- pRec
- 0.545
Intolerance Scores
- loftool
- 0.456
- rvis_EVS
- -0.08
- rvis_percentile_EVS
- 47.2
Haploinsufficiency Scores
- pHI
- 0.111
- hipred
- Y
- hipred_score
- 0.530
- ghis
- 0.534
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.694
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Apaf1
- Phenotype
- endocrine/exocrine gland phenotype; growth/size/body region phenotype; cellular phenotype; craniofacial phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; limbs/digits/tail phenotype; digestive/alimentary phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; reproductive system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; embryo phenotype; skeleton phenotype; vision/eye phenotype;
Gene ontology
- Biological process
- response to hypoxia;kidney development;neural tube closure;apoptotic process;activation of cysteine-type endopeptidase activity involved in apoptotic process;nervous system development;aging;response to nutrient;activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c;cardiac muscle cell apoptotic process;cell differentiation;forebrain development;regulation of apoptotic process;positive regulation of apoptotic process;neutrophil degranulation;protein homooligomerization;neuron apoptotic process;intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress;negative regulation of G0 to G1 transition;cellular response to transforming growth factor beta stimulus;response to G1 DNA damage checkpoint signaling;intrinsic apoptotic signaling pathway;regulation of apoptotic DNA fragmentation;positive regulation of apoptotic signaling pathway
- Cellular component
- extracellular region;nucleus;cytosol;protein-containing complex;secretory granule lumen;apoptosome;extracellular exosome;ficolin-1-rich granule lumen
- Molecular function
- nucleotide binding;protein binding;ATP binding;cysteine-type endopeptidase activator activity involved in apoptotic process;heat shock protein binding;identical protein binding;ADP binding